ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $53,731 | -42.1% | 11,194 | -9.4% | 0.00% | – |
| Q2 2023 | $92,839 | +104.5% | 12,362 | +23.1% | 0.00% | – |
| Q1 2023 | $45,394 | -44.4% | 10,043 | +38.7% | 0.00% | – |
| Q4 2022 | $81,617 | -94.4% | 7,242 | -91.6% | 0.00% | – |
| Q1 2022 | $1,455,000 | -27.8% | 86,072 | -8.2% | 0.00% | -100.0% |
| Q4 2021 | $2,016,000 | +275.4% | 93,798 | +1190.9% | 0.00% | – |
| Q3 2021 | $537,000 | +107.3% | 7,266 | +53.4% | 0.00% | – |
| Q2 2021 | $259,000 | -81.5% | 4,738 | -75.0% | 0.00% | – |
| Q1 2021 | $1,397,000 | +34825.0% | 18,948 | +37796.0% | 0.00% | – |
| Q4 2020 | $4,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |